Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.
You may also be interested in...
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
Roche presented data at ASCO on its two CD20-targeting bispecific antibodies, showing high response rates in heavily pretreated non-Hodgkin lymphoma patients.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.